ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1433

Clinical Characterization of Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease

Masaomi Yamasaki, Rheumatology, Shin-Yokohama Yamasaki Clinic, Yokohama, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ACPA, interstitial lung disease, radiology and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a common manifestation of rheumatoid lung disease.  Subclinical RA-ILD is most commonly identified on HRCT imaging. In this study, we aimed to define the clinical characteristics of subclinical RA-ILD on HRCT, and to analyze long-term prognosis of subclinical RA-ILD.

Methods

340 patients with RA were treated at our hospital and followed them up for three years or until development of symptomatic ILD. All patients were performed chest radiological examinations at the initial presentation. The HRCT findings which include (1) ground glass opacity, (2) air-space consolidation, linear opacity including (3) septal line and (4) non-septal line, (5) honeycomb lung, (6) traction bronchiectasis, (7)pleural irregularity, and (8)pleural effusion were scored as the CT scoring system. The extent of involvement of each abnormality was assessed independently for each of the three zones of each lung. The HRCT extent score was represented the sum of the score of each lung. HRCT parameters which included the extension score, ACPA and the clinical features at the initial presentation were retrospectively analyzed.

Results

76 (22.3%) out of 340 RA patients had abnormal chest radiological findings which consist with ILD.  5 out of 76 patients had shortness of breath and showed a rapidly progressive ILD (6.6%). The rest of 71 (48women, 23men) had subclinical RA-ILD who were either asymptomatic or have symptoms and physiologic abnormalities that are as yet unrecognized as being due to RA-ILD. There was no difference in the positive rates of anti-CCP2 between subclinical RA-ILD and clinical evident RA-ILD. However there were no difference in the HRCT findings which included nonseptal linear attenuation, ground-glass attenuation and air space consolidation between subclinical RA-ILD group and clinical RA-ILD group, subclinical RA-ILD group showed less degree in honeycombing (p=0.0003) and focal ILD (p=0.0061). There have only two cases lead to clinically evident RA-ILD within 6 months. These two cases were treated with azathioprine and with MMF showed stable ILD on HRCT.

Conclusion

HRCT finding focused on honeycombing and the extension score at the initial presentation is a sensitive technique for detection of subclinical RA-ILD. This study suggest the progression of asymptomatic radiologic changes could lead to the development of clinical RA-ILD.


Disclosure:

M. Yamasaki,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characterization-of-subclinical-rheumatoid-arthritis-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology